EGFR and adenocarcinoma: The use of EGFR inhibitors for lung adenocarcinoma since 2004 may explain the improvement in the survival of adenocarcinoma patients from 2000–2004 to 2005–2008, particularly for women, with improvement of the 1-, 3- and 5-year survival from 46.24%, 20.86%, and 15.26% in 1996–1999 to 64.53%, 31.81% and 19.86% in 2005–2008, respectively.